Assessment of the Outcomes of Intrahepatic Cholangiocarcinoma after Ultrasound-Guided Percutaneous Microwave Ablation Based on Albumin–Bilirubin Grade
Chinese PLA General Hospital,Cheng Zhigang,Han Zhiyu,Liu Fangyi,Yu Xiaoling,Yu Jie
DOI: https://doi.org/10.1007/s00270-020-02637-9
2020-01-01
CardioVascular and Interventional Radiology
Abstract:To determine whether albumin–bilirubin (ALBI) grade could be used to predict the outcomes of patients with intrahepatic cholangiocarcinoma (ICC) who underwent ultrasound-guided percutaneous microwave ablation (MWA). This retrospective study was approved by the institutional review board, and the requirement for informed consent was waived. We studied 52 treatment-naïve patients with 74 ICC lesions according to the Milan criteria who subsequently underwent MWA from April 2011 to March 2018. Overall survival (OS) and recurrence-free survival (RFS) were compared in groups classified by Child–Pugh score and ALBI grade, which were statistically analyzed with the log-rank test. Cox proportional hazard regression analyses were used to determine the prognostic factors for survival in patients with ICC. The median follow-up time was 21.2 months (3.2–78.7 months). Seventeen patients died during this period. After MWA, the cumulative 1-, 3-, and 5-year OS rates were 87.4%, 51.4%, and 35.2%, respectively, and the cumulative 1-, 3-, and 5-year RFS rates were 68.9%, 56.9%, and 56.9%, respectively. The major complication rate was 3.8% (2/52). Stratified according to ALBI grade, the cumulative 1-, 3-, and 5-year OS rates were 95.5%, 72.4%, and 72.4% for patients with ALBI grade 1 and 62.5%, 40.6%, and 36.3% for patients with ALBI grade 2, respectively, showing a significant difference (P = 0.006). Multivariate analysis results showed that older age (hazard ratio [HR]: 1.67, 95% confidence interval [CI]: 1.11–2.82; P = 0.002), tumor size ≥ 3 cm in diameter (HR: 11.33, CI: 2.24–34.52; P = 0.021) and ALBI grade (HR: 8.23, CI: 1.58–58.00; P = 0.004) may be predictors of poor OS. ALBI grade was validated as a significant biomarker for predicting survival in ICC patients within the Milan criteria who underwent MWA.